AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$URGN

Smith Jason Drew sold $65K of URGN

Smith Jason Drew (General Counsel) sold 1,519 shares of UroGen Pharma Ltd. (URGN) at $42.54 on 2026-09-08.

Original reporting
SEC EDGAR · Smith Jason Drew
Published Sep 9, 2026, 6:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$URGN
Neutral
high confidence
Mentioned
$URGN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$URGNNeutralLow
01

Why it matters

The transaction is a routine insider sale with limited market effect.

02

Market read

Minor relevance; informs investors of insider activity but unlikely to move the stock.

03

What to watch

Potential upcoming clinical data could influence insider behavior.

Relevance 3/10Novelty 4/10Timing: filed Sep 9, 2026 (post‑market)

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$URGNNeutralHigh confidence
Context

General Counsel sold 1,519 shares for $64.6K, reducing his stake to 53,141 shares.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is small relative to market cap and insider remains a large holder.

Market effects

Sector

None; biotech sector not affected by a single insider sale.

Regional

No regional impact.

Global

Low relevance to global markets.

Counterpoint

What could challenge this read

Insider may be diversifying; could signal confidence if other insiders are buying.

Key entities

  • person
    Smith Jason Drew

    General Counsel of UroGen Pharma Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

URGN insider trading history →

Related articles

OCT 19
$URGNHighAI 8/10

UroGen Secures FDA NDA Acceptance For Investigational Bladder Cancer Therapy

UroGen Pharma (URGN) announced FDA acceptance of its NDA for UGN-103, an investigational bladder cancer treatment. The FDA set a PDUFA target action date of June 14, 2027. The NDA is backed by Phase 3 UTOPIA trial data, showing a 77.8% complete response rate at three months. UGN-103 combines RTGel hydrogel with mitomycin. URGN shares are down 2.05% at $33.85.

rttnews.com2 min
OCT 19
$URGNMedAI 8/10

FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC

The FDA accepted UroGen Pharma's NDA for UGN-103, a treatment for recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer, with a PDUFA target action date of June 14, 2027. The application is backed by UTOPIA trial data showing a 77.8% complete response rate at 3 months and 94.5% event-free probability at 6 months among responders. UGN-103 uses a proprietary RTGel technology with mitomycin.

onclive.com2 min
OCT 19
$URGNHighAI 8/10

UroGen Pharma Announces FDA Acceptance Of UGN-103 NDA For Review

UroGen Pharma (URGN) announced FDA acceptance of the New Drug Application for UGN-103, a treatment for recurrent low-grade bladder cancer, with a PDUFA target action date of June 14, 2027. The NDA is supported by Phase 3 UTOPIA trial data. UroGen shares rose 0.69% to $34.80 in pre-market trading.

rttnews.com1 min
OCT 19
$URGNMedAI 8/10

FDA accepts UroGen’s drug application for bladder cancer

UroGen Pharma (URGN) announced the FDA accepted its New Drug Application for UGN-103, a treatment for recurrent low-grade bladder cancer. The FDA set a target review date of June 14, 2027. The application is supported by Phase 3 trial data showing a 77.8% complete response rate at three months. UroGen holds U.S. patents for the drug through July 2044.

investing.com2 min